INmune Bio Inc (INMB) Stock Analysis

AI analysis of INmune Bio Inc (INMB)

Hold

Currently, INmune Bio Inc (INMB) is not a strong buy. The stock is trading at $1.38, which is significantly below its 52-week high of $2.60, indicating a decline of about 47%. Additionally, the RSI is at 29.024, suggesting that the stock is oversold. However, the forward P/E ratio is 0, indicating no expected earnings growth in the near term, which raises concerns about the company's profitability. The main risk is the significant net loss reported in Q2, which was $1.27 million, down from $24.46 million the previous year, but still indicates ongoing financial challenges. Therefore, while there are some positive catalysts such as the submission of an Orphan Drug Application, the overall financial performance and technical indicators suggest holding rather than buying at this time.

Valuation Metrics

The current forward P/E ratio for INmune Bio Inc (INMB) is 0.00, compared to its 5-year average forward P/E of -3.83.

Forward P/E

Strongly Overvalued

5Y Average P/E

-3.83

Current P/E

0.00

Overvalued

-2.62

Undervalued

-5.04

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-0.00

Current EV/EBITDA

0.00

Overvalued

0.00

Undervalued

-0.00

Forward P/S

Fair

5Y Average P/S

1145.35

Current P/S

4.32

Overvalued

3291.36

Undervalued

-1000.67

Alphio AI Price Scenarios for INMB

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%INMB

$23.16

Scenario price

B

Base

Base · 50%INMB

$15.12

Scenario price

B

Bear

Bear · 25%INMB

$14.81

Scenario price

INMB FAQ — answered by Alphio AI

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Currently, INmune Bio Inc (INMB) is not a strong buy. The stock is trading at $1.38, which is significantly below its 52-week high of $2.60, indicating a decline of about 47%. Additionally, the RSI is at 29.024, suggesting that the stock is oversold. However, the forward P/E ratio is 0, indicating no expected earnings growth in the near term, which raises concerns about the company's profitability. The main risk is the significant net loss reported in Q2, which was $1.27 million, down from $24.46 million the previous year, but still indicates ongoing financial challenges. Therefore, while there are some positive catalysts such as the submission of an Orphan Drug Application, the overall financial performance and technical indicators suggest holding rather than buying at this time.